Charles River Laboratories Partners with MEDIPOST to Expand GMP Testing for Cell Therapies
Event summary
- Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. signed a non-exclusive MOU to collaborate on GMP-compliant testing and commercialization of cell therapies.
- The partnership will initially focus on the Asia-Pacific and North America regions, with potential expansion into the Middle East and Europe.
- CRL will provide biologics quality control, viral testing, and release testing services to support MEDIPOST’s global cell therapy pipeline.
- MEDIPOST has treated over 36,000 patients in South Korea with its commercial-stage allogeneic stem cell product, CARTISTEM®.
The big picture
The partnership underscores the growing demand for specialized GMP testing services in the cell therapy sector, particularly as companies like MEDIPOST seek to expand globally. This collaboration also highlights the strategic importance of the APAC region in the development and commercialization of advanced biologics. The non-exclusive nature of the MOU suggests that both companies are positioning themselves to explore additional partnerships in the future.
What we're watching
- Regulatory Expansion
- The pace at which the partnership can navigate and comply with regulatory frameworks in new regions, particularly the Middle East and Europe.
- Market Penetration
- Whether MEDIPOST can leverage CRL’s expertise to accelerate the commercialization of its cell therapy products in North America and APAC.
- Competitive Dynamics
- How this collaboration affects the competitive landscape for GMP testing services in the cell therapy sector.
Related topics